EGFR and neoplasm: To this end, a recombinant T-bsAb against EGFR on tumor cells and CD3 on T cells (EGFR-CD3 bsAb) was used to perform T cell-mediated killing in a coculture system of primary T cells with a panel of breast cancer cell lines, including basal-like (BT-549 and MDA-MB-231), luminal (MCF7), and HER2+ (SKBR3 and MDA-MB-453) subtypes, in the presence or absence of RNase1 (Figure 5G).